MAXVAX Biotechnology

Executive Summary

MAXVAX Biotechnology is a preclinical-stage Chinese biopharmaceutical company dedicated to developing innovative vaccine and immunotherapy platforms for infectious diseases and oncology. Founded in 2015 and headquartered in Beijing, the company leverages proprietary technologies to create more potent and broadly protective vaccines. With a lean team of 1-50 employees, MAXVAX focuses on addressing unmet medical needs in areas such as viral infections and therapeutic cancer vaccines. Despite being privately held and lacking disclosed funding or valuation, the company's positioning in the rapidly growing Chinese vaccine market and its dual focus on infectious disease and oncology differentiate it from many peers. However, as a preclinical entity, MAXVAX faces significant development and regulatory risks, and its progress depends on successful preclinical validation and eventual clinical trials.

Upcoming Catalysts (preview)

• 2027Initiation of first-in-human trials for lead vaccine candidate20% success
• Q4 2026Preclinical data publication or presentation at major conference40% success
• 2027Strategic partnership or licensing deal with larger pharma15% success